Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma

Maximilian Merz, MD, Thomas Hielscher, Anja Seckinger, MD, Dirk Hose, MD, Uta Bertsch, MD, Kai Neben, MD, Marc S Raab, MD, Igor Blau, Hans Walter Lindemann, MD, Ingo GH Schmidt-Wolf, MD, Christof Scheid, MD PhD, Mathias Haenel, MD, Katja Weisel, MD, Hartmut Goldschmidt, MD, Anna Jauch, PhD, Jens Hillengass, MD

Blood (2016) 128 (22): 4415.

https://doi.org/10.1182/blood.V128.22.4415.4415

Published: 2016

Journal Articles

Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4

Elias Karl Mai, MD, Christina Kunz, PhD, Uta Bertsch, MD, Hans-Juergen Salwender, MD, Michael Pfreundschuh, MD, Ulrich Duehrsen, MD, Peter Brossart, MD, Norma Peter, MD, Kai Neben, MD, Thomas Hielscher, Jens Hillengass, MD, Hans Martin, MD, Hans Walter Lindemann, MD, Christof Scheid, MD PhD, Katja C. Weisel, Igor W. Blau, MD, Hartmut Goldschmidt, MD

Blood (2015) 126 (23): 3187.

https://doi.org/10.1182/blood.V126.23.3187.3187

Published: 2015

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

Journal Articles

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Blood (2013) 122 (21): 3369.

https://doi.org/10.1182/blood.V122.21.3369.3369

Published: 2013

Journal Articles

Impact Of Response Duration and Maintenance Therapy After Autologous Stem Cell Transplantation On Long-Term Survival In Multiple Myeloma Patients

Nicola Lehners, MD, Christiane Heiss, Soh-Yun Kim, Thomas Hielscher, Jens Hillengass, MD, Gerlinde Egerer, MD, Anthony D. Ho, MD, Kai Neben, MD, Hartmut Goldschmidt, MD, Marc S. Raab, MD

Blood (2013) 122 (21): 3183.

https://doi.org/10.1182/blood.V122.21.3183.3183

Published: 2013

Journal Articles

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

Mathias Witzens-Harig, MD, Dirk Hose, MD, PhD, Simone Jünger, Christina Pfirschke, Nisit Khandelwal, Anja Seckinger, MD, Heinke Conrad, Bettina Brackertz, Thierry Reme, Brigittte Gückel, Tobias Meissner, Michael Hundemer, Anthony D Ho, MD, Jean-Francois Rossi, MD, PhD, Kai Neben, MD, Helga Bernhard, MD, Hartmut Goldschmidt, MD, Bernard Klein, Philipp Beckhove

Blood (2012) 120 (21): 2942.

https://doi.org/10.1182/blood.V120.21.2942.2942

Published: 2012

Journal Articles

Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.

Jens Hillengass, MD, Kerstin Kilk, MD, Karin Listl, Thomas Hielscher, Kai Neben, MD, Dirk Hose, MD, PhD, Marc-André Weber, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Ola Landgren, M.D., Ph.D.

Blood (2012) 120 (21): 2911.

https://doi.org/10.1182/blood.V120.21.2911.2911

Published: 2012

Journal Articles

Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.

Kai Neben, MD, Leopold Sellner, MD, Christiane Heiss, Dipl.Stat, Axel Benner, Dipl.Stat., Marc S Raab, MD, Jens Hillengass, MD, Dirk Hose, MD, PhD, Nicola Lehners, MD, Gerlinde Egerer, MD, Anthony D Ho, MD, Hartmut Goldschmidt, MD, PhD

Blood (2012) 120 (21): 3086.

https://doi.org/10.1182/blood.V120.21.3086.3086

Published: 2012

Journal Articles

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

Nikhil C. Munshi, MD, Rafat Abonour, MD, Joseph T. Beck, MD, William Bensinger, MD, Thierry Facon, MD, Keith Stockerl-Goldstein, MD, Rachid Baz, MD, David S Siegel, MD, PhD., Kai Neben, MD, Sagar Lonial, MD, Attaya Suvannasankha, MD, Sanela Bilic, PharmD, Sandra Chica, Subhendu Mukhopadhyay, Randi Isaacs, Sundar Jagannath, MD

Blood (2012) 120 (21): 331.

https://doi.org/10.1182/blood.V120.21.331.331

Published: 2012

Journal Articles

Aurora-A Polymorphisms in Multiple Myeloma: Implications On Chromosomal Instability

Ludmila Weiz, Suzin Choi, PhD, Niels Weinhold, PhD, Kai Neben, MD, Anthony D Ho, MD, Hartmut Goldschmidt, MD, PhD, Kari Hemminki, PhD, Alwin Krämer, MD, Marc S Raab, MD

Blood (2012) 120 (21): 3982.

https://doi.org/10.1182/blood.V120.21.3982.3982

Published: 2012

Journal Articles

BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications

Nicola Lehners, MD, Mindaugas Andrulis, MD, David Capper, MD, Andreas von Deimling, MD, Anthony D Ho, MD, Hartmut Goldschmidt, MD, Kai Neben, MD, Marc S Raab, MD

Blood (2012) 120 (21): 4040.

https://doi.org/10.1182/blood.V120.21.4040.4040

Published: 2012

Journal Articles

Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity

Jens Hillengass, MD, Kerstin Kilk, MD, Karin Listl, Thomas Hielscher, Kai Neben, MD, Dirk Hose, MD, PhD, Anthony D. Ho, MD, Marc-André Weber, MD, Ola Landgren, M.D., Ph.D., Hartmut Goldschmidt, MD

Blood (2012) 120 (21): 4966.

https://doi.org/10.1182/blood.V120.21.4966.4966

Published: 2012

Journal Articles

The Chromosomal Abnormalities Del(17p), t(4;14), and +1q21 Predict Progression From Smoldering to Symptomatic Multiple Myeloma

Kai Neben, MD, Anna Jauch, PhD, Thomas Hielscher, Jens Hillengass, MD, Nicola Lehners, MD, Marc S Raab, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD

Blood (2012) 120 (21): 1806.

https://doi.org/10.1182/blood.V120.21.1806.1806

Published: 2012

Journal Articles

Metascoring and Gene Expression Profiling in Clinical Routine in Multiple Myeloma,

Tobias Meißner, Anja Seckinger, Thierry Rème, Thomas Hielscher, Thomas Möhler, Kai Neben, MD, Hartmut Goldschmidt, MD, Bernard Klein, Dirk Hose

Blood (2011) 118 (21): 3940.

https://doi.org/10.1182/blood.V118.21.3940.3940

Published: 2011

Journal Articles

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Tilmann Bochtler, MD, Ute Hegenbart, MD, Axel Benner, Dirk Hose, MD, Anja Seckinger, Kai Neben, MD, Sascha Dietrich, MD, Claus R Bartram, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Anna Jauch, PhD, Stefan O Schonland, MD

Blood (2011) 118 (21): 3946.

https://doi.org/10.1182/blood.V118.21.3946.3946

Published: 2011

Journal Articles

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

Blood (2011) 118 (21): 332.

https://doi.org/10.1182/blood.V118.21.332.332

Published: 2011

Journal Articles

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Mathias Witzens-Harig, MD, Axel Benner, Michael Rieger, MD, Fabienne McClanahan, MD, Manfred Hensel, MD, Kai Neben, MD, Peter Dreger, MD, Eva Lengfelder, MD, Ingo Schmidt-Wolf, MD, Alwin Krämer, MD, PhD, Anthony D. Ho, MD

Blood (2011) 118 (21): 3700.

https://doi.org/10.1182/blood.V118.21.3700.3700

Published: 2011

Journal Articles

Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,

Ute Hegenbart, MD, Stefan O Schonland, MD, Axel Benner, Christina Wunder, Thomas M. Moehler, PD, Dr., Jens Hillengass, Martin Görner, Jana Schlenzka, Kai Neben, MD, Peter Dreger, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2011) 118 (21): 4124.

https://doi.org/10.1182/blood.V118.21.4124.4124

Published: 2011

Journal Articles

Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation

Jens Hillengass, Sofia Ayyaz, Kerstin Kilk, Marc André Weber, Thomas Hielscher, Hans-Ulrich Kauczor, Stefan Delorme, Anthony D. Ho, Hartmut Goldschmidt, Kai Neben, MD

Blood (2011) 118 (21): 1812.

https://doi.org/10.1182/blood.V118.21.1812.1812

Published: 2011

Journal Articles

Reapplication of High-Dose Chemotherapy with Melphalan Followed by Autologous Hematopoietic Stem Cell Transplantation as Salvage Therapy for Patients with Relapsed Multiple Myeloma

Leopold Sellner, MD, Sonja Teodorov, Christiane Heiss, Axel Benner, Gerlinde Egerer, MD, Peter Dreger, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Kai Neben, MD

Blood (2010) 116 (21): 3568.

https://doi.org/10.1182/blood.V116.21.3568.3568

Published: 2010

NARROW

Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma

Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Impact Of Response Duration and Maintenance Therapy After Autologous Stem Cell Transplantation On Long-Term Survival In Multiple Myeloma Patients

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.

Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

Aurora-A Polymorphisms in Multiple Myeloma: Implications On Chromosomal Instability

BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications

Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity

The Chromosomal Abnormalities Del(17p), t(4;14), and +1q21 Predict Progression From Smoldering to Symptomatic Multiple Myeloma

Metascoring and Gene Expression Profiling in Clinical Routine in Multiple Myeloma,

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,

Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation

Reapplication of High-Dose Chemotherapy with Melphalan Followed by Autologous Hematopoietic Stem Cell Transplantation as Salvage Therapy for Patients with Relapsed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only